Literature DB >> 971703

Comparative clinical pharmacology of intravenous cefoxitin and cephalothin.

P F Sonneville, R R Kartodirdjo, H Skeggs, A E Till, C M Martin.   

Abstract

Intravenous doses of 0.5, 1, and 2 g cephalothin and cefoxitin, a semi-synthetic cephamycin antibiotic highly resistant to bacterial cephalosporinase, were infused over a period of 3 minutes into 18 normal adult males by a randomized, crossover design. Serum and urine data on cefoxitin best fit a two-compartment open model. Serum concentrations following cefoxitin were higher and more prolonged and urine recoveries higher than those following equal doses of cephalothin. The terminal serum half-life of cefoxitin was longer at all dose levels. Renal clearance of cephalothin-like activity exceeded that of cefoxitin, which may possess dose-dependent kinetics. Whereas cephalothin has been reported to metabolize by greater than 35% to the less active desacetyl form, cefoxitin was metabolized by 0.1 to 6% to the descarbamyl form in individual subjects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971703     DOI: 10.1007/BF00606555

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  CEPHALOTHIN SERUM LEVELS IN THE AZOTEMIC PATIENT.

Authors:  S A KABINS; S COHEN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

2.  Analysis of cefoxitin, cephalothin and their deacylated metabolites in human urine by high-performance liquid chromatography.

Authors:  R P Buhs; T E Maxim; N Allen; T A Jacob; F J Wolf
Journal:  J Chromatogr       Date:  1974-11-06

3.  An in vivo comparison of cefoxitin, a semi-synthetic cephamycin, with cephalothin.

Authors:  J M Hamilton-Miller; D W Kerry; W Brumfitt
Journal:  J Antibiot (Tokyo)       Date:  1974-01       Impact factor: 2.649

4.  Comparison of cefazolin, a new cephalosporin antibiotic, with cephalothin.

Authors:  J P Phair; J Carleton; J S Tan
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

5.  Pharmacokinetics of phosphonomycin in Man. I. Intravenous administration.

Authors:  K C Kwan; D A Wadke; E L Foltz
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

6.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.

Authors:  W M Kirby; J B De Maine; W S Serrill
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

7.  Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin.

Authors:  R C Moellering; M Dray; L J Kunz
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

8.  Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

Authors:  W Brumfitt; J Kosmidis; J M Hamilton-Miller; J N Gilchrist
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

9.  Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; H Kropp; E O Stapley; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

10.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

View more
  10 in total

1.  Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.

Authors:  Arantxazu Isla; Iñaki F Trocóniz; Ignacio López de Tejada; Silvia Vázquez; Andrés Canut; Jesús Muriel López; María Ángeles Solinís; Alicia Rodríguez Gascón
Journal:  Eur J Clin Pharmacol       Date:  2012-01-15       Impact factor: 2.953

2.  A new beta-lactam antibiotic: is it a major advance?

Authors:  H C Neu
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

3.  Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.

Authors:  M Ohkawa; M Orito; T Sugata; M Shimamura; M Sawaki; E Nakashita; K Kuroda; K Sasahara
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

4.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin.

Authors:  P F Sonneville; K S Albert; H Skeggs; H Gentner; K C Kwan; C M Martin
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

6.  Antibiotic prophylaxis in gynecology: cefoxitin concentrations in serum, myometrium, endometrium and salpinges.

Authors:  F Daschner; E Petersen; H Langmaack; M Trennhäuser
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

7.  Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.

Authors:  H Ko; K S Cathcart; D L Griffith; G R Peters; W J Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

8.  Use of adjuvants for enhancement of rectal absorption of cefoxitin in humans.

Authors:  S S Davis; W R Burnham; P Wilson; J O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 9.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

Review 10.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.